Tag: Tumor Blood Testing Market Trends

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Tumor Blood Testing Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The tumor blood testing market has experienced substantial expansion in recent times. This market is projected to expand from $5.98 billion in 2025 to $6.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.3%. Historically, this growth has been driven by several factors, including an increase in cancer prevalence, the constraints of tissue biopsy, breakthroughs in genomic testing, investment in oncology research funding, and the rising demand for non-invasive diagnostic methods.

The tumor blood testing market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $11.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. This projected growth is driven by factors such as the implementation of early cancer screening initiatives, advancements in AI-enabled genomic analysis, the rise of personalized medicine, broader use of companion diagnostics, and increased adoption in clinical trials. Key developments anticipated during this period encompass the widespread adoption of liquid biopsies, advancements in multi-cancer early detection, enhanced minimal residual disease monitoring, tailored oncology testing, and the identification of high-sensitivity biomarkers.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=35065291&type=smp&name=Tumor%20Blood%20Testing%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Tumor Blood Testing Market Growth Factors Behind Sustained Expansion

The rising incidence of cancer is anticipated to propel the expansion of the tumor blood testing market over the next few years. An aging global demographic and exposure to various risk factors, including inadequate nutrition, tobacco use, and environmental contaminants, are leading to a greater occurrence of cancer, thereby boosting the need for swift diagnostic techniques. This method, known as tumor blood testing, offers a non-invasive way to identify cancer prior to the onset of symptoms through the detection of specific biomarkers present in the bloodstream. Such testing facilitates prompt diagnosis, earlier therapeutic intervention, enhanced patient prognoses, and continuous observation of disease advancement and the efficacy of treatments. To illustrate, in May 2024, data from the National Cancer Institute, a US-based government agency, indicated that by January 2022, approximately 18.1 million cancer survivors resided in the United States, with forecasts suggesting this figure will climb to 26 million by 2040. Consequently, the growing frequency of cancer cases is a primary factor stimulating the expansion of the tumor blood testing market.

Tumor Blood Testing Market Segment Analysis Spotlighting Growth Areas

The tumor blood testing market covered in this report is segmented –

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types

2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays

3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma

4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells

2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA

3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes

4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

Tumor Blood Testing Market Industry Trends Fueling Future Revenue Growth

Leading firms within the tumor blood testing market are concentrating on advancing novel technologies, particularly non-invasive liquid biopsy methods, to improve the efficiency of early cancer detection, treatment monitoring, and disease progression assessment. These non-invasive liquid biopsy technologies represent diagnostic tools that identify and evaluate cancer-associated biomarkers present in bodily fluids, offering a safer and more user-friendly option compared to conventional tissue biopsies. An example of this innovation is the launch in February 2024 of the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test designed for cancer monitoring, by US-based biotechnology company Delfi Diagnostics in partnership with UK-based biotechnology company Immunocore Holdings plc. This assay functions by examining cell-free DNA (cfDNA) fragments found in the bloodstream to determine tumor burden and gauge response to treatment. Such a fragmentome-based liquid biopsy presents a non-invasive and economical alternative to established approaches, needing only a small amount of plasma and delivering results within two weeks.

Tumor Blood Testing Market Industry Leaders And Competitive Landscape

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

View The Full Tumor Blood Testing Market Report:

https://thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Tumor Blood Testing Market Regional Analysis And Top Geography

North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

The tumor blood testing market is gaining significant traction as advances in medical technology and rising cancer rates drive demand for less invasive diagnostic options. With continuous innovations and expanding applications, this sector is set for rapid growth, presenting valuable opportunities for healthcare providers, researchers, and patients alike. Let’s explore the current market size, key factors propelling growth, leading players, and emerging trends shaping the future of tumor blood testing.

Rapid Expansion in Tumor Blood Testing Market Size

The tumor blood testing market has experienced strong growth recently and is projected to rise from $5.98 billion in 2025 to $6.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.3%. This increase during the historical period has been driven by factors such as the rising incidence of cancer, limitations associated with traditional tissue biopsies, advancements in genomic testing technologies, increased funding for oncology research, and heightened demand for non-invasive diagnostic methods. Looking ahead, the market is expected to grow even faster, reaching $11.13 billion by 2030 at a CAGR of 13.2%. Key drivers during the forecast period include the expansion of early cancer screening programs, the integration of AI-enabled genomic analysis, growth in personalized medicine, broader adoption of companion diagnostics, and increased utilization of clinical trials. Important trends shaping the future include wider liquid biopsy use, multi-cancer early detection technologies, monitoring minimal residual disease, personalized oncology testing, and advancements in high-sensitivity biomarker detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp

Factors Behind Tumor Blood Testing Market Expansion

One of the primary factors boosting growth in the tumor blood testing market is the increasing prevalence of cancer worldwide. Aging populations, along with exposure to risk factors such as unhealthy diets, smoking, and environmental pollution, have contributed to a surge in cancer cases. This, in turn, drives demand for early and accurate detection methods. Tumor blood testing offers a minimally invasive way to detect cancer biomarkers circulating in the bloodstream, allowing for earlier diagnosis before symptoms become evident. This enables timely therapeutic intervention, better patient outcomes, and ongoing disease monitoring. For example, in May 2024, the National Cancer Institute reported that as of January 2022, there were approximately 18.1 million cancer survivors in the United States, with projections estimating this number to rise to 26 million by 2040. This rising cancer population underscores the urgent need for improved diagnostic tools like tumor blood testing.

Key Revenue Drivers in Tumor Blood Testing Market Segmentation

The tumor blood testing market is segmented into various categories to better understand its dynamics:

– By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, and other types.

– By Technology: Polymerase Chain Reaction (PCR)-based testing, Next-Generation Sequencing, and Immunoassays.

– By Cancer Type: Breast, Colorectal, Lung, Prostate, and Melanoma cancers.

– By Application: Early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.

– By End User: Hospitals, diagnostic laboratories, research institutes, and other users.

Access The Complete Tumor Blood Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

Within these segments are further subcategories such as CTC tests focusing on isolation, enumeration, and characterization of tumor cells; CtDNA tests analyzing mutations, methylation, copy number variations, and fragmentation; exosome-based tests profiling proteins, RNA, lipids, and surface markers; and other tests including circulating RNA assays, tumor-educated platelet tests, protein biomarker panels, multiomics blood tests, and immuno-oncology biomarker evaluations.

Emerging Technologies Shaping Tumor Blood Testing Market Growth

Leading companies in the tumor blood testing space are heavily focused on pioneering non-invasive liquid biopsy technologies to improve early cancer detection and treatment monitoring. These technologies analyze cancer-related biomarkers from body fluids, presenting a safer alternative to traditional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a US biotech firm, partnered with UK-based Immunocore Holdings to launch the DELFI-Tumor Fraction (DELFI-TF) assay. This blood test examines cell-free DNA fragments circulating in the blood to evaluate tumor burden and treatment response. The fragmentome-based liquid biopsy offers a cost-effective and minimally invasive option, requiring small plasma volumes and delivering results within two weeks, enhancing patient convenience and clinical decision-making.

Leading Organizations Driving Competition in Tumor Blood Testing Market

The tumor blood testing market is highly competitive, with several key players shaping its future. Prominent companies include Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., and Menarini Silicon Biosystems S.p.A. These organizations are investing heavily in research and development to create innovative products and expand the reach of tumor blood testing.

Regional Market Distribution Trends Driving Growth

In 2025, North America held the largest share of the tumor blood testing market, benefiting from advanced healthcare infrastructure and extensive research activities. Meanwhile, the Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, due to increasing healthcare investments, growing cancer awareness, and expanding diagnostic capabilities. Other key regions covered in the market report include South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, each contributing uniquely to global market dynamics and expansion opportunities.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Tumor Blood Testing Market Over The 2026–2030 Period?

The tumor blood testing market has experienced rapid expansion in its size over recent years. It is projected to grow from $5.98 billion in 2025 to $6.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.3%. This historical growth can be primarily attributed to the rise in cancer prevalence, limitations of tissue biopsy, advancements in genomic testing, oncology research funding, and a strong demand for non-invasive diagnostics.

The tumor blood testing market is anticipated to experience significant expansion in the coming years. This market is projected to reach $11.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this growth during the forecast period include early cancer screening programs, AI-enabled genomic analysis, the rise of personalized medicine, the broadening scope of companion diagnostics, and increased adoption in clinical trials. Key trends observed in this period encompass the widespread adoption of liquid biopsy, advancements in multi-cancer early detection, enhanced minimal residual disease monitoring, specialized personalized oncology testing, and the development of high-sensitivity biomarker detection methods.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

Which Important Drivers Are Guiding The Tumor Blood Testing Market Growth?

The rising incidence of cancer is anticipated to propel expansion within the tumor blood testing market over the next few years. Demographic shifts towards older populations, coupled with exposure to various risk factors like unhealthy eating habits, tobacco use, and environmental contaminants, are leading to a greater number of cancer cases, thereby boosting the need for early diagnostic tools. Tumor blood testing offers a less invasive way to identify cancer by detecting specific biomarkers in the bloodstream even before clinical symptoms manifest. This method facilitates prompt diagnosis, allows for earlier therapeutic interventions, enhances patient recovery prospects, and permits continuous tracking of disease advancement and treatment efficacy. For example, data from May 2024, provided by the National Cancer Institute, a US-based government agency, indicated that the United States had approximately 18.1 million cancer survivors as of January 2022, with forecasts suggesting this figure will climb to 26 million by 2040. Consequently, the expanding occurrence of cancer is a key factor stimulating the growth of the tumor blood testing market.

How Is The Tumor Blood Testing Market Broken Down By Segment Categories?

The tumor blood testing market covered in this report is segmented –

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types

2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays

3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma

4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells

2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA

3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes

4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

What Trends Are Influencing The Evolution Of The Tumor Blood Testing Market?

Leading companies in the tumor blood testing market are concentrating on developing innovative technologies, such as non-invasive liquid biopsy techniques, to enable earlier cancer detection, monitor treatment efficacy, and assess disease progression more effectively. These non-invasive liquid biopsy technologies are diagnostic tests that detect and analyze cancer-related biomarkers from bodily fluids, offering a safer and more convenient option than traditional tissue biopsies. For example, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, launched the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test for cancer monitoring. This assay analyzes cell-free DNA (cfDNA) fragments in the bloodstream to assess tumor burden and treatment response. This fragmentome-based liquid biopsy presents a non-invasive, cost-effective alternative to traditional methods, requiring minimal plasma and yielding results within two weeks.

Which Players Are Present In The Tumor Blood Testing Market Space?

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Get The Full Tumor Blood Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

Which Region Leads The Tumor Blood Testing Market In Overall Market Size?

North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Tumor Blood Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2026, By The Business Research Company

Hemato Oncology Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Blood Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Tumor Blood Testing Market Between 2026 And 2030?

The tumor blood testing market has seen rapid growth in recent years. It is projected to expand from $5.98 billion in 2025 to $6.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. Historically, this growth can be attributed to factors such as an increase in cancer prevalence, the limitations associated with tissue biopsies, progress in genomic testing, greater funding for oncology research, and a rising demand for non-invasive diagnostic solutions.

The tumor blood testing market size is projected to see significant expansion in the coming years. It is expected to grow to $11.13 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 13.2%. This growth during the forecast period can be attributed to factors such as early cancer screening programs, AI-enabled genomic analysis, the evolution of personalized medicine, the broader application of companion diagnostics, and increased adoption in clinical trials. Major trends anticipated in this period include the widespread adoption of liquid biopsy, the development of multi-cancer early detection methods, enhanced minimal residual disease monitoring, advancements in personalized oncology testing, and the identification of high-sensitivity biomarkers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Tumor Blood Testing Market?

The escalating occurrence of cancer is projected to propel the expansion of the tumor blood testing market over the next few years. Demographic shifts towards older populations, coupled with exposure to various risk factors like unhealthy eating habits, tobacco use, and environmental contamination, are contributing to a greater number of cancer cases, thereby boosting the need for timely diagnostic techniques. This method, known as tumor blood testing, offers a less intrusive way to identify cancer markers in the bloodstream, allowing for detection prior to the onset of overt symptoms. Such capabilities facilitate prompt diagnoses, earlier therapeutic interventions, better results for patients, and continuous surveillance of disease advancement and treatment efficacy. For instance, in May 2024, the National Cancer Institute, a US-based government agency, reported that as of January 2022, the United States had an estimated 18.1 million cancer survivors, with projections expected to reach 26 million by 2040. Consequently, the rising occurrence of cancer is significantly propelling the expansion of the tumor blood testing market.

Which Market Segments Are Examined In The Tumor Blood Testing Market Study?

The tumor blood testing market covered in this report is segmented –

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types

2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays

3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma

4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells

2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA

3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes

4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

Which Trends Are Influencing The Tumor Blood Testing Market?

Key companies in the tumor blood testing industry are channeling their efforts into developing cutting-edge technologies, such as non-invasive liquid biopsy methods, to enable earlier detection of cancer, monitor the efficacy of treatments, and more efficiently assess the progression of diseases. Non-invasive liquid biopsy technologies are diagnostic examinations that detect and analyze cancer-related biomarkers from bodily fluids, presenting a safer and more convenient option compared to traditional tissue biopsies. For example, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, launched the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test for cancer monitoring. It scrutinizes cell-free DNA (cfDNA) fragments within the bloodstream to gauge tumor burden and how well treatment is working. This fragmentome-based liquid biopsy provides a non-invasive, cost-effective alternative to existing methods, requiring only a minimal plasma sample and yielding results within two weeks.

Who Are The Primary Competitors In The Tumor Blood Testing Market?

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Read the full tumor blood testing market report here:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

What Are The Leading Geographic Regions In The Tumor Blood Testing Market?

North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tumor Blood Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp

Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2026, By The Business Research Company

Hemato Oncology Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Blood Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

How is the Tumor Blood Testing Market size predicted to change over the forecast window of 2026–2035?

The tumor blood testing market size has shown substantial growth over recent years. This market is expected to expand from $5.98 billion in 2025 to $6.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. The growth observed in the past can be linked to an increase in cancer prevalence, inherent limitations of tissue biopsy, ongoing advancements in genomic testing, consistent oncology research funding, and a rising demand for non-invasive diagnostics.

The tumor blood testing market size is projected to experience substantial expansion over the coming years. This market is set to reach $11.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. This anticipated growth during the forecast period stems from factors such as the implementation of early cancer screening programs, advancements in AI-enabled genomic analysis, the rise of personalized medicine, the broader use of companion diagnostics, and increased adoption in clinical trials. Key developments shaping the market within this period encompass the widespread adoption of liquid biopsy, multi-cancer early detection initiatives, sophisticated minimal residual disease monitoring, the proliferation of personalized oncology testing, and the evolution of high-sensitivity biomarker detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp

Which Drivers Are Contributing To The Expansion Of The Tumor Blood Testing Market?

The rising incidence of cancer is anticipated to propel the expansion of the tumor blood testing market in the foreseeable future. An aging demographic and exposure to various risk factors, including inadequate nutrition, tobacco use, and environmental contaminants, are leading to a greater occurrence of cancer, thereby boosting the need for early detection solutions. Tumor blood testing offers a non-invasive way to identify cancer through biomarkers in the bloodstream prior to the onset of noticeable symptoms. Such testing facilitates prompt diagnosis, allows for early intervention, enhances patient results, and permits continuous tracking of disease advancement and treatment efficacy. For example, in May 2024, data from the National Cancer Institute, a US-based government agency, indicated that as of January 2022, approximately 18.1 million cancer survivors resided in the United States, with forecasts predicting this number to climb to 26 million by 2040. Consequently, the expanding occurrence of cancer is a key factor propelling the development of the tumor blood testing market.

What Segment Categories Are Covered In The Tumor Blood Testing Market?

The tumor blood testing market covered in this report is segmented –

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types

2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays

3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma

4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells

2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA

3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes

4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

What Trends Are Projected To Support The Growth Of The Tumor Blood Testing Market?

Leading companies in the tumor blood testing sector are concentrating on developing innovative technologies, particularly non-invasive liquid biopsy techniques, to enable earlier detection of cancer, monitor the effectiveness of treatments, and more efficiently assess disease progression. These non-invasive liquid biopsy technologies are diagnostic examinations that identify and analyze cancer-related biomarkers from bodily fluids, presenting a safer and more convenient option than traditional tissue biopsies. For example, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, introduced the DELFI-Tumor Fraction (DELFI-TF) assay, which is a blood test for monitoring cancer. This assay functions by analyzing cell-free DNA (cfDNA) fragments within the bloodstream to evaluate tumor burden and how well a patient is responding to treatment. This particular fragmentome-based liquid biopsy provides a non-invasive, cost-efficient alternative to conventional approaches, requiring minimal plasma and delivering results within two weeks.

Which Leading Companies Dominate The Tumor Blood Testing Market Share?

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Tumor Blood Testing Market?

North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Tumor Blood Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp

Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2026, By The Business Research Company

Hemato Oncology Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Blood Screening Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Tumor Blood Testing Industry In 2025?

The size of the tumor blood testing market has expanded significantly over recent years. This market is projected to expand from $5.27 billion in 2024 to reach $5.98 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 13.5%. Historically, this expansion can be ascribed to increased research in genomics and proteomics, a growing patient need for quick test outcomes, the surge in developing targeted therapies that necessitate companion diagnostics, the expanding practice of decentralized diagnostics, and a heightened patient inclination towards sample collection at home.

The tumor blood testing market is projected to experience substantial growth over the next few years. Its valuation is anticipated to reach $9.83 billion in 2029, growing at a compound annual growth rate (CAGR) of 13.2%. This expansion during the forecast period is attributed to several factors, including an increase in the adoption of point-of-care testing solutions, greater clinical validation of novel blood tests, a rise in government and private funding for cancer research, the enhanced availability of high-sensitivity tumor biomarkers, and a growing patient preference for less invasive procedures. Key trends anticipated during this period include advancements in multi-cancer early detection (MCED) tests, progress in companion diagnostics, innovative applications of synthetic biology in diagnostics, the integration of blockchain for data security in diagnostics, and the incorporation of robotics in laboratory processes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp

What Are The Top Growth Drivers Impacting The Tumor Blood Testing Market Outlook?

The rising incidence of cancer is anticipated to propel the expansion of the tumor blood testing market in the foreseeable future. Older populations, alongside exposure to risk elements like unhealthy eating habits, tobacco use, and environmental contaminants, are leading to a greater occurrence of cancer, thereby boosting the need for early detection solutions. Tumor blood testing offers a non-invasive method to identify cancer prior to symptom onset, achieved by detecting specific biomarkers present in the bloodstream. This facilitates prompt diagnosis, allows for initial treatment, enhances patient results, and permits continuous tracking of disease advancement and treatment efficacy. For example, data from May 2024 from the National Cancer Institute, a US-based government entity, indicated that by January 2022, approximately 18.1 million cancer survivors were present in the United States, with forecasts suggesting this number will climb to 26 million by 2040. Consequently, the growing frequency of cancer is a key factor boosting the expansion of the tumor blood testing market.

What Are The Key Segments In The Tumor Blood Testing Market?

The tumor blood testing market covered in this report is segmented as

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types

2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Microarray-Based Testing, Mass Spectrometry, Immunoassays

3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma

4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells

2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA

3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes

4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

How Are Trends Influencing The Tumor Blood Testing Market?

Leading companies operating within the tumor blood testing market are concentrating on developing innovative technologies, such as non-invasive liquid biopsy methods, to facilitate early cancer detection, track treatment efficacy, and evaluate disease progression more effectively. These non-invasive liquid biopsy technologies represent diagnostic tests that identify and analyze cancer-related biomarkers from bodily fluids, offering a safer and more convenient alternative to conventional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, introduced the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test designed for cancer monitoring. This assay examines cell-free DNA (cfDNA) fragments within the bloodstream to determine tumor burden and assess the response to treatment. This fragmentome-based liquid biopsy serves as a non-invasive, cost-effective option compared to traditional approaches, requiring only a minimal amount of plasma and yielding results within two weeks.

Who Are The Core Companies Influencing The Tumor Blood Testing Market Landscape?

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

How Is Tumor Blood Testing Market Demand Varying Across Different Regions?

North America was the largest region in the tumor blood testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumor blood testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Tumor Blood Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp

Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2025, By The Business Research Company

Solid Tumor Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

Hemato Oncology Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model